Bioton

Recombinant insulin & biosimilars · Diabetes

Overview

One of few global manufacturers of recombinant human insulin (Gensulin), exporting to dozens of markets and developing insulin-analog biosimilars.

What they do

Bioton is a Polish biopharmaceutical company and one of the relatively few global manufacturers of recombinant human insulin, sold under the Gensulin brand. Listed on the Warsaw Stock Exchange, it produces classical human insulins at scale and is developing insulin-analog biosimilars to broaden its diabetes portfolio. Insulin is exported to dozens of markets, particularly in Asia.

Lead program & status

Gensulin is a commercial product, not a pipeline asset; at the end of December 2024 it reportedly held about 42% of the classical insulin market in Poland. Exports are a key growth driver: full-year 2024 insulin exports reportedly reached around PLN 116 million (up from roughly PLN 80 million in 2023), with major markets including Malaysia, Vietnam, China and Thailand. In November 2024 Bioton signed a commercial licence-and-supply agreement with a global pharma company for a biosimilar long-acting insulin analogue (glargine), with a planned Polish launch following reimbursement around mid-2025.

Why it matters

Bioton secures regional access to affordable insulin and represents one of Central Europe's most established biologics-manufacturing capabilities.

FAQ

What is Gensulin?

Gensulin is Bioton's brand of recombinant human insulin, a commercial product exported to dozens of markets and a leader in Poland's classical insulin segment.

Is Bioton expanding into insulin analogs?

Yes. Bioton is developing insulin-analog biosimilars and in November 2024 signed a licence-and-supply deal for a biosimilar long-acting insulin analogue (glargine).

Where does Bioton export insulin?

Key export markets reportedly include Malaysia, Vietnam, China and Thailand, with full-year 2024 insulin exports of roughly PLN 116 million.

Company website / source ↗ Open the interactive map →